Unidad de Investigación Clínica de Oncohematología Pediátrica IdiPAZ-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Oncohematología Pediátrica IdiPAZ-CNIO

Antonio Pérez
Antonio Pérez Jefe de Unidad de Investigación Clínica
T +34 917328000 (Ext )
anperezm@ext.cnio.es

Investigadores Científicos

  • Sara Carpintero

Investigador Clínico I

  • Carmen Mestre

Becarios Post-doctorales

  • Cristina Aguirre
  • Halin Bareke
  • Elisa Pilar Izquierdo
  • Adriana Mañas
  • Jordi Minguillón
  • Andrés París
  • Odelaisy León Triana

Becarios Pre-Doctorales

  • Karima Al Akioui
  • Laura Clares
  • Mikel Fernández
  • Adrián Ibáñez
  • Antonio Jesús Muñoz
  • Sara Naharro
  • Alfonso Navarro
  • Beatriz Ruz
  • Clara Venegas

Técnicos de Laboratorio

  • Lidia Pertiñez
  • Natalia Riestra

The Pediatric Onco-Hematology Clinical Research Unit, headed by Antonio Pérez-Martínez, comprises a multidisciplinary team of physicians, geneticists, biologists, biochemists, and bioinformaticians, who, for the past decade, have carried out projects ranging from knowledge generation to direct clinical application through the development of clinical trials. Our research, which is mostly funded by Fundación Cris Contra el Cáncer, focuses on the design of therapies applied to paediatric oncology, infectious diseases, and paediatric transplantation. Briefly, our research interests include: 1) the use of haematopoietic stem cell transplantation as a platform for cell therapy; 2) the improvement of human stem cell progenitors transplantation in children; 3) cell therapy with memory T lymphocytes as adoptive immunotherapy; and 4) the use of both activated and memory-like NK cells and CART-T cells in paediatric oncology. Together with this, we led several projects aimed at studying the efficacy and feasibility of cell therapy against infectious diseases. Finally, we are also working on the induction of immunological tolerance in solid organ transplantation by inducing mixed haematopoietic chimera through cell therapy. We maintain a strong commitment to patients and to improving their quality of life, having a direct impact on society’s well-being. In this sense, we have several active academic clinical trials and collaborations with industry, with the objective of developing new and more effective therapies with fewer side effects.

Publicaciones

    SELECT dxsjj_posts.* FROM dxsjj_posts LEFT JOIN dxsjj_postmeta ON ( dxsjj_posts.ID = dxsjj_postmeta.post_id ) LEFT JOIN dxsjj_postmeta AS mt1 ON ( dxsjj_posts.ID = mt1.post_id AND mt1.meta_key = 'factor_impacto' ) LEFT JOIN dxsjj_postmeta AS mt2 ON ( dxsjj_posts.ID = mt2.post_id ) LEFT JOIN dxsjj_postmeta AS mt3 ON ( dxsjj_posts.ID = mt3.post_id ) LEFT JOIN dxsjj_postmeta AS mt4 ON ( dxsjj_posts.ID = mt4.post_id ) WHERE 1=1 AND ( ( dxsjj_postmeta.meta_key = 'factor_impacto' OR mt1.post_id IS NULL ) AND mt2.meta_key = 'autores' AND ( mt3.meta_key = 'id_grupos' AND mt3.meta_value LIKE '{b4b37f45d5e04b4cb3de62f8efe1e61408f5dce6a047458a71d295057c388a18}50012146{b4b37f45d5e04b4cb3de62f8efe1e61408f5dce6a047458a71d295057c388a18}' ) AND ( mt4.meta_key = 'anyo' AND CAST(mt4.meta_value AS SIGNED) >= '2019' ) ) AND dxsjj_posts.post_type = 'cnio_publication' AND ((dxsjj_posts.post_status = 'publish')) GROUP BY dxsjj_posts.ID ORDER BY CAST(mt4.meta_value AS SIGNED) DESC, CAST(dxsjj_postmeta.meta_value AS SIGNED) DESC, CAST(mt2.meta_value AS CHAR) ASC

  • París-Muñoz A, León-Triana O, Pérez-Martínez A, Barber DF (2024). Helios as a potential biomarker in systemic lupus erythematosus and new therapies based on immunosuppressive cells. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES , 1187665. Publicación CNIO.

Subir